Navigation Links
Study on PLC Systems' TMR Therapy With Stem Cells Presented at ESC 2009
Date:9/14/2009

FRANKLIN, Mass., Sept. 14 /PRNewswire-FirstCall/ -- PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that a paper on a clinical study utilizing its Transmyocardial Laser Revascularization (TMR) therapy in conjunction with autologous stem cells was presented at ESC Congress 2009, the annual meeting of the European Society of Cardiology, in Barcelona, Spain.

This study is designed to examine the safety and feasibility of transplanting stem cells during TMR used in combination with coronary bypass grafting in patients with end-stage heart failure. According to the initial results of the study, this procedure was effective in improving cardiac function, as assessed by echocardiography and magnetic resonance imaging prior to therapy and post surgery, as well as three, six and twelve months afterwards. In addition, the treatment thus far has proven feasible and safe; no intra- or post-operative major adverse cardiac events occurred in the patients enrolled in the study.

This investigator-sponsored study, called INSTEM, is on-going in Germany under the leadership of Dr. Hans-Michael Klein, Associate Professor in the Department of Thoracic and Cardiovascular Surgery at Dusseldorf Medical School in Germany, who presented the initial results at a session on Saturday, August 29th.

Mark R. Tauscher, president and chief executive officer of PLC Systems, said, "We have been monitoring the work of Dr. Klein and others in utilizing our TMR therapy in conjunction with stem cells for some time, and thus we are quite pleased to see the positive initial results of his clinical study presented to an important audience like ESC. Should such a therapy be proven effective, it would provide a new avenue of treatment for heart failure patients, who number approximately 5 million in the U.S. alone and millions more worldwide."

"The combination of CD133+ stem cell transplantation and surgical myocardial revascularization promises to be a new and enhanced causal therapy of severe ischemic cardiomyopathy," stated Dr. Klein. "Although the follow-up has not yet been completed, we can strongly suppose that this procedure significantly augments improvement in left ventricle function."

About PLC Systems Inc.

PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Massachusetts, PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. PLC's newest product, RenalGuard(R), is approved for sale in the EU as a general fluid balancing device. Additional company information can be found at www.plcmed.com.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that the final results of the INSTEM trial may be different from the initial trial results, the combination of TMR and stem cell therapy may not be adopted widely or at all in clinical practice, we may be unable to raise sufficient funds in the future to implement our business plan, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2008, and our other SEC reports.

PLC Systems, PLC and CO2 Heart Laser and RenalGuard are trademarks of PLC Systems Inc.

    Contact:  Mary T. Conway
    Conway Communications
    617-244-9682
    mtconway@att.net


'/>"/>
SOURCE PLC Systems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients
2. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
3. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
4. NovaBay Launches Clinical Study for Non-Antibiotic Treatment of Impetigo, One of the Most Common Skin Infections
5. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
6. BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury
7. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
8. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
9. Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra(TM) in RA
10. Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
11. Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):